Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/24/2021 - 06:30 AM
CAMBRIDGE, Mass. --(BUSINESS WIRE)--
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1 at 8:30am ET .
A live webcast of the fireside chat can be accessed on the Investor page of Sage’s website at investor.sagerx.com . A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20211124005771/en/
Investor
Helen Rubinstein
Helen.Rubinstein@sagerx.com
Media
Maureen L. Suda
Maureen.Suda@sagerx.com
Source: Sage Therapeutics, Inc.
SAGE Rankings
#4744 Ranked by Stock Gains
SAGE Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About SAGE
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
